 The purpose of this Phase IIIb study is to evaluate the immunogenicity, reactogenicity safety of GSK Biologicals Hib-MenC vaccine MenitorixTM when co-administered with GSK Biologicals DTPa-HBV-IPV vaccine InfanrixTM penta Wyeths 7-valent pneumococcal conjugate vaccine PrevenarTM in preterm infants as a 3-dose primary vaccination course during the first 6 months of life at 2, 4, 6 months of age and of a booster dose of MenitorixTM when co-administered with GSK Biologicals DTPa-IPV vaccine Infanrix IPV and Wyeths Prevenar in the second year of life 16-18 months of age. The control is a group of full-term infants receiving the same vaccines. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. 